These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 25443348)

  • 1. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.
    Hoshida Y; Fuchs BC; Bardeesy N; Baumert TF; Chung RT
    J Hepatol; 2014 Nov; 61(1 Suppl):S79-90. PubMed ID: 25443348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.
    Przybyszewski EM; Chung RT
    J Infect Dis; 2023 Sep; 228(Suppl 3):S226-S231. PubMed ID: 37703341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of interferon therapy in treatments for hepatitis C virus-related hepatocellular carcinoma].
    Kubo S; Nishiguchi S; Hirohashi K; Tanaka H; Shuto T; Takemura S; Shiomi S; Kinoshita H
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):1975-9. PubMed ID: 11791377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.
    Della Corte C; Aghemo A; Colombo M
    World J Gastroenterol; 2013 Mar; 19(9):1359-71. PubMed ID: 23538741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Direct-Acting Antivirals for Hepatitis C Virus and the Risk for Hepatocellular Carcinoma.
    Chinchilla-López P; Qi X; Yoshida EM; Méndez-Sánchez N
    Ann Hepatol; 2017; 16(3):328-330. PubMed ID: 28425400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of hepatitis C-associated hepatocellular carcinoma.
    Liang TJ; Heller T
    Gastroenterology; 2004 Nov; 127(5 Suppl 1):S62-71. PubMed ID: 15508105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.
    Wirth TC; Manns MP
    Ann Oncol; 2016 Aug; 27(8):1467-74. PubMed ID: 27226385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
    Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
    Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis.
    Li DK; Chung RT
    Cancer; 2015 Sep; 121(17):2874-82. PubMed ID: 26079399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular Carcinoma Chemoprevention with Generic Agents.
    Rasha F; Paul S; Simon TG; Hoshida Y
    Semin Liver Dis; 2022 Nov; 42(4):501-513. PubMed ID: 36104114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of antiviral treatment for HCC prevention.
    Colombo M; Iavarone M
    Best Pract Res Clin Gastroenterol; 2014 Oct; 28(5):771-81. PubMed ID: 25260307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: the prevention of hepatitis B-related hepatocellular carcinoma.
    Lin CL; Kao JH
    Aliment Pharmacol Ther; 2018 Jul; 48(1):5-14. PubMed ID: 29722445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon for decreasing the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Hayashi N; Kasahara A
    Oncology; 2002; 62 Suppl 1():87-93. PubMed ID: 11868793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma: paradigm of preventive oncology.
    O'Brien TR; Kirk G; Zhang M
    Cancer J; 2004; 10(2):67-73. PubMed ID: 15130266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
    Michielsen P; Ho E; Francque S
    Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
    Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL;
    Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
    Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma and hepatitis C in the United States.
    El-Serag HB
    Hepatology; 2002 Nov; 36(5 Suppl 1):S74-83. PubMed ID: 12407579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection.
    Hayes CN; Zhang P; Zhang Y; Chayama K
    Viruses; 2018 Sep; 10(10):. PubMed ID: 30274202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.